Bioptik Technology (ROCO:4161) ROCE %: 11.82% (As of Dec. 2025)

What is Bioptik Technology ROCE %?

Bioptik Technology ROCO:4161 68 ROCE % is 11.82% as of Dec. 2025. GuruFocus rates ROCO:4161 with a GF Score™ of 68/100 and a GF Value™ of NT$27.79 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioptik Technology's annualized ROCE % for the quarter that ended in Dec. 2025 was 11.82%.

Bioptik Technology (ROCO:4161) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bioptik Technology ROCE % Related Terms

Bioptik Technology ROCE % Historical Data

* Premium members only.

The historical data trend for Bioptik Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioptik Technology ROCE % Chart

Bioptik Technology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

2.87

7.95

12.51

11.82

8.74

Bioptik Technology Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															14.66	7.74	3.11	12.55	11.82

68GF Score

Bioptik Technology Inc ROCO:4161

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bioptik Technology ROCE % Calculation

Bioptik Technology's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	92.93	/	( ( (1487.743 - 448.262)	+	(1571.836 - 484.398) )	/ 2 )
	=	92.93	/	( (1039.481	+	1087.438)	/ 2 )
	=	92.93	/	1063.4595
	=	8.74 %

Bioptik Technology's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	127.224	/	( ( (1462.348 - 397.265)	+	(1571.836 - 484.398) )	/ 2 )
	=	127.224	/	( ( 1065.083	+	1087.438 )	/ 2 )
	=	127.224	/	1076.2605
	=	11.82 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 11.82% mean?

Bioptik Technology (ROCO:4161) has a ROCE % of 11.82% as of Dec. 2025.

Is Bioptik Technology's ROCE % too high?

Bioptik Technology's current ROCE % is 11.82%. The Medical Devices & Instruments industry median ROCE % is 2.30. Bioptik Technology's value of 11.82% is 415% above this industry median. Overall, Bioptik Technology has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Bioptik Technology's ROCE % compare to ABT and SYK?

Bioptik Technology's ROCE % of 11.82% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. Bioptik Technology's value of 11.82% is 415% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioptik Technology's current ROCE % of 11.82% is 415% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current ROCE % is 11.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bioptik Technology stock overvalued right now?

Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$23.00 — trading 17.2% below its estimated fair value. The current ROCE % is 11.82% and 415% above the Medical Devices & Instruments industry median of 2.30. Bioptik Technology's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current ROCE % is 11.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioptik Technology (ROCO:4161) Overvalued in 2026?

Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued. The current stock price of NT$23.00 is trading 17.2% below its estimated GF Value™ of NT$27.79. GuruFocus considers Bioptik Technology to be Modestly Undervalued.

Key valuation signals for ROCO:4161:

ROCE %: 11.82%
GF Value™: NT$27.79 vs. price of NT$23.00 (17.2% below fair value)
GF Score™: 68/100 with 2 warning signs
Industry Position: 415% above the Medical Devices & Instruments median

No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioptik Technology Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ROCO:6815 ROCO:6872 ROCO:4735 ROCO:4121 ROCO:6649 ROCO:6767 ROCO:4198 ROCO:4745 ROCO:3373 ROCO:6572 ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057

Website http://www.bioptik.com.tw

Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.

68GF Score

Get the complete analysis for ROCO:4161

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.00

Price

NT$27.79

GF Value

View ROCO:4161 Analysis

See ROCE % data for all stocks →